Literature DB >> 33129638

Depression: An actionable outcome for those at clinical high-risk.

Jean Addington1, Megan S Farris2, Lu Liu2, Kristin S Cadenhead3, Tyrone D Cannon4, Barbara A Cornblatt5, Thomas H McGlashan6, Diana O Perkins7, Larry J Seidman8, Ming T Tsuang3, Elaine F Walker9, Carrie E Bearden10, Daniel H Mathalon11, William S Stone8, Matcheri Keshevan8, Scott W Woods6.   

Abstract

Comorbid diagnoses are common in youth who are at clinical high-risk (CHR) for developing psychosis, with depression being the most common. The aim of this paper is to examine depression over two years in a large sample of CHR youth who do not make the transition to psychosis, considering both categorical and dimensional ratings of depression severity. The sample consisted of 267 CHR youth who were followed for two years. Based on DSM-IV diagnoses over this time period, 100 CHR individuals never received a diagnosis of depression, 64 individuals continuously met criteria for depression, 92 individuals received a diagnosis of depression at one or more timepoints, and 11 participants had a diagnosis of depression only at 24-months. These groupings were supported by six-monthly ratings on the Calgary Depression Scale. The majority of this sample experienced a major depressive episode on more than one occasion, suggesting that depression and depressive symptoms identify a domain of substantial unmet clinical need. Recommendations are that depression in CHR youth and young adults should be monitored more frequently and that there is a need for clinical trials to address depression systematically in this vulnerable population.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Clinical high-risk; Depression; Prognosis; Psychosis; Symptoms

Mesh:

Year:  2020        PMID: 33129638      PMCID: PMC7854482          DOI: 10.1016/j.schres.2020.10.001

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  32 in total

1.  Reliability and validity of a depression rating scale for schizophrenics.

Authors:  D Addington; J Addington; E Maticka-Tyndale; J Joyce
Journal:  Schizophr Res       Date:  1992-03       Impact factor: 4.939

2.  North American Prodrome Longitudinal Study (NAPLS 2): overview and recruitment.

Authors:  Jean Addington; Kristin S Cadenhead; Barbara A Cornblatt; Daniel H Mathalon; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Scott W Woods; Jack A Addington; Tyrone D Cannon
Journal:  Schizophr Res       Date:  2012-10-06       Impact factor: 4.939

3.  Lack of Diagnostic Pluripotentiality in Patients at Clinical High Risk for Psychosis: Specificity of Comorbidity Persistence and Search for Pluripotential Subgroups.

Authors:  Scott W Woods; Albert R Powers; Jerome H Taylor; Charlie A Davidson; Jason K Johannesen; Jean Addington; Diana O Perkins; Carrie E Bearden; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Thomas H McGlashan
Journal:  Schizophr Bull       Date:  2018-02-15       Impact factor: 9.306

4.  Clinical and functional characteristics of youth at clinical high-risk for psychosis who do not transition to psychosis.

Authors:  Jean Addington; Jacqueline Stowkowy; Lu Liu; Kristin S Cadenhead; Tyrone D Cannon; Barbara A Cornblatt; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Carrie E Bearden; Daniel H Mathalon; Olga Santesteban-Echarri; Scott W Woods
Journal:  Psychol Med       Date:  2018-09-04       Impact factor: 7.723

5.  A depression rating scale for schizophrenics.

Authors:  D Addington; J Addington; B Schissel
Journal:  Schizophr Res       Date:  1990 Jul-Aug       Impact factor: 4.939

6.  Calgary Depression Scale for Schizophrenia: a study of the validity of a French-language version in a population of schizophrenic patients.

Authors:  D Bernard; C Lançon; P Auquier; G Reine; D Addington
Journal:  Acta Psychiatr Scand       Date:  1998-01       Impact factor: 6.392

7.  Cross-cultural adaptation and validation of the Spanish version of the Calgary Depression Scale for Schizophrenia.

Authors:  Salvador Sarró; Rosa M Dueñas; Nicolás Ramírez; Belén Arranz; Ramón Martínez; José M Sánchez; José M González; Laura Saló; Luisa Miralles; Luis San
Journal:  Schizophr Res       Date:  2004-06-01       Impact factor: 4.939

8.  Characterizing Covariant Trajectories of Individuals at Clinical High Risk for Psychosis Across Symptomatic and Functional Domains.

Authors:  Dana M Allswede; Jean Addington; Carrie E Bearden; Kristin S Cadenhead; Barbara A Cornblatt; Daniel H Mathalon; Thomas McGlashan; Diana O Perkins; Larry J Seidman; Ming T Tsuang; Elaine F Walker; Scott W Woods; Tyrone D Cannon
Journal:  Am J Psychiatry       Date:  2019-09-06       Impact factor: 18.112

9.  Exploration of clinical high-risk dropouts.

Authors:  Jacqueline Stowkowy; Lu Liu; Kristin S Cadenhead; Ming T Tsuang; Tyrone D Cannon; Barbara A Cornblatt; Thomas H McGlashan; Scott W Woods; Diana O Perkins; Larry J Seidman; Elaine F Walker; Carrie E Bearden; Daniel H Mathalon; Jean Addington
Journal:  Schizophr Res       Date:  2017-09-28       Impact factor: 4.939

10.  Multidisciplinary Treatment for Individuals at Clinical High Risk of Developing Psychosis.

Authors:  Jean Addington; Daniel J Devoe; Olga Santesteban-Echarri
Journal:  Curr Treat Options Psychiatry       Date:  2019-01-31
View more
  2 in total

1.  Commentary. Toward a core outcomes assessment set for clinical high risk.

Authors:  Scott W Woods; Catalina V Mourgues-Codern; Albert R Powers
Journal:  Schizophr Res       Date:  2020-05-12       Impact factor: 4.939

2.  Ketamine Induces Lasting Antidepressant Effects by Modulating the NMDAR/CaMKII-Mediated Synaptic Plasticity of the Hippocampal Dentate Gyrus in Depressive Stroke Model.

Authors:  Idriss Ali Abdoulaye; Shan-Shan Wu; Enkhmurun Chibaatar; Da-Fan Yu; Kai Le; Xue-Jin Cao; Yi-Jing Guo
Journal:  Neural Plast       Date:  2021-04-23       Impact factor: 3.144

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.